Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the relative abuse potential of two
different doses of orally administered Acurox Tablets to orally administered
immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.
Phase:
Phase 2
Details
Lead Sponsor:
Acura Pharmaceuticals Inc.
Collaborator:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer